Compare Agilent Technologies Inc (A) vs Cintas Corporation (CTAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Cintas Corporation — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Cintas Corporation trades at $205.78 (market cap $81.25B). The key difference: Cintas Corporation is the larger of the two by market cap, and Cintas Corporation pays the higher dividend (1.02%). Which is the better fit depends on your goals.
| A | CTAS | |
|---|---|---|
Market Cap | $42.00B | $81.25B |
Sector | Health | Industrials |
52-Week High | $157.20 | $225.10 |
52-Week Low | $110.24 | $163.55 |
Enterprise Value | $43.55B | $83.67B |
Dividend Yield | 0.69% | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
Cintas (CTAS) trades at $203.05, up 0.45% on the day, with a bullish technical signal and strong fundamental performance. The company reported Q2 2026 EPS of $1.29, beating estimates, and revenue growth continues with a 17.75% net income margin. Recent news highlights Bank of America's upgrade to 'Buy' and a quarterly dividend announcement, reflecting confidence in its outlook.
The outlook for CTAS is positive, supported by consistent earnings beats and robust profitability, though high valuation multiples like a P/E of 41.35 pose a risk. Upside exists toward the consensus price target of $225.83, but investors should monitor competitive pressures and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →
